EHMT2 and Alzheimer disease: Specifically, this synergistic interaction between G9a inhibition (via UNC0642) and CB1R activation (via ACEA) arises from complementary molecular mechanisms that enhance neuroprotective signaling pathways while mitigating neuroinflammation and synaptic dysfunction in AD models.